Hansa Biopharma (HNSAS) Stock Overview
A biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
HNSAS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Hansa Biopharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 24.11 |
| 52 Week High | SEK 24.11 |
| 52 Week Low | SEK 24.10 |
| Beta | 1.52 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -61.21% |
| 5 Year Change | -89.56% |
| Change since IPO | -84.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| HNSAS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 9.0% | 2.2% |
| 1Y | n/a | 9.8% | 13.4% |
Return vs Industry: Insufficient data to determine how HNSAS performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how HNSAS performed against the UK Market.
Price Volatility
| HNSAS volatility | |
|---|---|
| HNSAS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: HNSAS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine HNSAS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 140 | Renee Aguiar-Lucander | www.hansabiopharma.com |
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis.
Hansa Biopharma AB (publ) Fundamentals Summary
| HNSAS fundamental statistics | |
|---|---|
| Market cap | SEK 2.94b |
| Earnings (TTM) | -SEK 596.68m |
| Revenue (TTM) | SEK 196.47m |
Is HNSAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HNSAS income statement (TTM) | |
|---|---|
| Revenue | SEK 196.47m |
| Cost of Revenue | SEK 63.66m |
| Gross Profit | SEK 132.81m |
| Other Expenses | SEK 729.49m |
| Earnings | -SEK 596.68m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 30, 2025
| Earnings per share (EPS) | -7.04 |
| Gross Margin | 67.60% |
| Net Profit Margin | -303.70% |
| Debt/Equity Ratio | -202.9% |
How did HNSAS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/21 17:45 |
| End of Day Share Price | 2025/06/25 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hansa Biopharma AB (publ) is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Christian Lee | ABG Sundal Collier Sponsored |
| Madhu Kumar | B. Riley Securities, Inc. |